[1] Fan L, Strasser-Weippl K, Li JJ,et al. Breast cancer in China[J].Lancet Oncol,2014, 15(7): e279-89. [2] Cardoso F, Loibl S, Pagani O, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer[J].Eur J Cancer,2012, 48(18):3355-3377. [3] Lakhani SR, Ellis OI, Schnitt SJ, et al. WHO Classification of Tumors of the Breast[M].Lyon: Editors IARC Press,2012: 60-61. [4] 施晓通, 沈建国, 王林波. 年轻乳腺癌患者临床特征的研究[J].肿瘤, 2014, 34(12): 1138-1143. [5] 汤红平,谢闺娥,黄犁,等. 106例青年女乳腺癌临床病理特点的回顾性分析[J].中华乳腺病杂志, 2013,7(3):184-187. [6] Tichy JR, Lim E, Anders CK. Breast cancer in adolescents and young adults: a review with a focus on biology[J].J Natl Compr Canc Netw,2013, 11(9): 1060-1069. [7] Wang Y, Cao S, Chen Y. Molecular treatment of different breast cancers[J].Anticancer Agents Med Chem,2015, 15(6): 701-720. [8] Mannell A. The role of Ki-67 in breast cancer[J].S Afr J Surg,2016, 54(2): 10-13. [9] Calhoun BC, Collins LC. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting[J].Semin Diagn Pathol,2015, 32(5): 362-369. [10] Periyasamy M, Patel H, Lai CF, et al. APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer[J].Cell Rep,2015, 13(1):108-121. [11] Narod SA. Breast cancer in young women[J].Nat Rev Clin Onconl,2012, 9(8): 460-470. [12] Tsoutsou PG, Vozenin MC, Durham AD, et al. How could breast cancer molecular features contribute to locoregional treatment decision making[J].Crit Rev Oncol Hematol,2017, 110: 43-48. [13] 张敏敏.35岁以下女性乳腺癌患者临床病理特征分析:附85例报告[J].中国普通外科杂志, 2014, 23(5): 665-669. [14] Alco G, Bozdogan A, Selamoglu D, et al. Clincal and histopathological factors associated with Ki-67 expression in breast cancer patients[J].Asian Pac J Cancer Prev,2015, 16(2): 823-829. [15] Petrelli F, Viale G, Cabiddu M, et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients[J].Breast Cancer Res Treat,2015, 153(3):477-491.